An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-07056-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Hiroyuki Suzuki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan. h.suzuki@chiba-u.jp. Hauptthemen laut MEDLINE: alpha-MSH, Melanoma, Astatine, Molecular Targeted Therapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Purpose
Patients who develop metastatic melanoma have a very poor prognosis, and new treatments are needed to improve the response rates. Melanocortin-1 receptor (MC1R) is a promising target for radionuclide therapy of metastatic melanoma, and alpha-melanocyte stimulating hormone (α-MSH) peptide analogs show high affinities to MC1Rs. Because targeted alpha therapy (TAT) can be a desirable treatment for metastatic melanoma, this study aimed to develop an 211 At-labeled α-MSH peptide analog for TAT of metastatic melanoma.
Methods
We designed an α-MSH analog labeled with 211 At using a neopentyl glycol scaffold via a hydrophilic linker. Preliminary studies using 125 I-labeled α-MSH analogs were performed to identify suitable hydrophilic linkers. Then, [ 211 At]NpG-GGN 4c was prepared using a procedure similar to that of the 125 I-labeled counterpart, [ 125 I]NpG-GGN 4b . The biodistribution profile of [ 211 At]NpG-GGN 4c in B16F10 tumor-bearing mice was compared with that of [ 125 I]NpG-GGN 4b . B16F10 tumor-bearing mice were treated with a single dose of vehicle or [ 211 At]NpG-GGN 4c (1 or 0.4 MBq ) .
Results
The D-Glu-D-Arg linker was identified as the optimal hydrophilic linker because of its high affinity for MC1R and good biodistribution profile, especially with low accumulation in the liver and intestine. [ 211 At]NpG-GGN 4c showed tumor accumulation comparable to that of [ 125 I]NpG-GGN 4b and maintained the tumor radioactivity retention from 1 to 3 h postinjection. [ 211 At]NpG-GGN 4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss. Conclusion [ 211 At]NpG-GGN 4c showed dose-dependent efficacy against B16F10 xenografts, suggesting that [ 211 At]NpG-GGN 4c is a promising TAT agent for treating metastatic melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan. h.suzuki@chiba-u.jp.
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8675, Japan.
- Department of Quantum-Applied Biosciences, Takasaki Institute for Advanced Quantum Science, National Institutes for Quantum Science and Technology, Watanuki, Takasaki, 1233, 370-1292, Gunma, Japan.
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Department of Radiology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, 565-0871, Osaka, Japan.
- Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, 279-0013, Chiba, Japan.
ORCID-Profile: Hiroyuki Suzuki, Kento Kannaka, Shigeki Watanabe, Kazuhiro Ooe, Tadashi Watabe, Hiroshi Tanaka, Tomoya Uehara
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Suzuki, H., Yamashita, S., Tanaka, S., Kannaka, K., Sasaki, I., Ohshima, Y., Watanabe, S., Ooe, K., Watabe, T., Ishioka, N. S., Tanaka, H., & Uehara, T. (2025). An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07056-3
Vancouver
Suzuki H, Yamashita S, Tanaka S, Kannaka K, Sasaki I, Ohshima Y, et al. An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07056-3
BibTeX
@article{Suzuki2025,
author = {Suzuki, Hiroyuki and Yamashita, Saki and Tanaka, Shoko and Kannaka, Kento and Sasaki, Ichiro and Ohshima, Yasuhiro and Watanabe, Shigeki and Ooe, Kazuhiro and Watabe, Tadashi and Ishioka, Noriko S and Tanaka, Hiroshi and Uehara, Tomoya},
title = {An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-07056-3}
}
EUVIMED